Transplanting own stem cells into heart of severe angina patients lessens their pain and improves their ability to walk, a new study has revealed.
The largest national stem cell study for heart disease showed that transplant subjects also experienced fewer deaths than those who didn’t receive stem cells.
In the 12-month Phase II, double-blind trial, subjects’ own purified stem cells, called CD34+ cells, were injected into their hearts in an effort to spur the growth of small blood vessels that make up the microcirculation of the heart muscle (…)
He also said that this study provides the first evidence that a person’s
TaiGen Biotechnology Co., Ltd. announced today that in a phase 1 study in healthy volunteers TG-0054, a chemokine receptor CXCR4 antagonist, was well tolerated and rapidly mobilized stem cells and endothelial progenitor cells from bone marrow into peripheral blood. The number of CD34+ stem cells in circulation after one dose of TG-0054 was equal or higher than reported cell numbers needed for stem cell transplantation in cancer patients. The observed AEs were all mild and transient. A phase 2 study in stem cell transplantation for multiple myeloma, non-Hodgkin lymphoma and Hodgkin disease patients is currently being initiated (…)
Doctors hope a Nottinghamshire boy with leukaemia can undergo a stem cell transplant in May.
Roman Cusick, from Calverton, is currently recovering from chemotherapy.
If he is deemed to be well enough, he will receive cells from an umbilical cord from a German donor in a procedure at Sheffield Children’s Hospital.
In February almost 200 people in Calverton helped took part in a saliva test to see if they were a suitable match.
Leukaemia occurs when large numbers of white blood cells take over the bone marrow, leaving the body unable to produce enough normal blood cells.
Leukemia, the most common form of childhood cancer, affects the blood-forming cells in the bone marrow. It is often treated with stem cell transplants that replace the patient’s bone marrow cells with stem cells donated by a healthy individual. Successful transplant depends on finding a donor who is a close genetic match to the patient. That’s a particular challenge for patients from racial and ethnic minority groups, who may die while waiting for a matching donor.
But a mostly-untapped source of genetically diverse stem cells is right under our noses: Blood left in the umbilical cord after a baby is
A new treatment regimen can help some patients who have blood cancer to live disease-free longer, University of Floridaresearchers and colleagues have found.
Low doses of a drug called lenalidomide can help hold off the return of multiple myeloma after bone marrow transplantation. Patients who took the drug to maintain health also lived longer than those who did not take the drug.
“In choosing maintenance therapy we look at a few things,” said study co-author Dr. Jan S. Moreb, clinical director of hematologic malignancies in the UF College of Medicine’s division of hematology/oncology and a member of the UF Shands Cancer